Preventing tuberculosis with community-based care in an HIV-endemic setting: a modeling analysis.

Jennifer M. Ross^{1*§}, Chelsea Greene^{2*}, Cara J. Bayer³, David W. Dowdy⁴, Alastair van Heerden^{5,6}, Jesse Heitner⁷, Darcy W. Rao⁸, D. Allen Roberts⁹, Adrienne E. Shapiro^{1,10}, Zelda B. Zabinsky², Ruanne V. Barnabas^{7,11}

^{*} These authors contributed equally

1. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA

2. Department of Industrial and Systems Engineering, University of Washington, Seattle, USA

3. Department of Epidemiology, University of North Carolina, Chapel Hill, USA

4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

5. Centre for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa

6. SAMRC/Wits Developmental Pathways for Health Research Unit, University of the Witwatersrand, Johannesburg, South Africa

- 7. Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA
- 8. Bill & Melinda Gates Foundation, Seattle, USA

9. Department of Epidemiology, University of Washington, Seattle, USA

- 10. Department of Global Health, University of Washington, Seattle, USA
- 11. Harvard Medical School, Boston, USA

[§] Corresponding author: Jennifer M. Ross

International Clinical Research Center University of Washington 325 9th Avenue, Box 359927 Seattle, WA 98104 USA +1-206-543-9192 Jross3@uw.edu

Keywords: Differentiated care, cost effectiveness, gender, modeling, TB, HIV epidemiology

Word count:

Abstract: 345/350

Main text: 3487/3500

1 Abstract

2 Introduction:

Antiretroviral therapy (ART) and TB preventive treatment (TPT) both prevent tuberculosis (TB) disease and deaths among people living with HIV. Differentiated care models, including community-based care, can increase uptake of ART and TPT to prevent TB in settings with a high burden of HIV-associated TB, particularly among men.

7 Methods:

We developed a gender-stratified dynamic model of TB and HIV transmission and disease 8 progression among 100,000 adults ages 15-59 in KwaZulu-Natal, South Africa. We drew model 9 10 parameters from a community-based ART initiation and resupply trial in sub-Saharan Africa (Delivery Optimization for Antiretroviral Therapy, DO ART) and other scientific literature. We 11 simulated the impacts of community-based ART and TPT care programs during 2018-2027, 12 13 assuming that community-based ART and TPT care were scaled up to similar levels as in the DO 14 ART trial (i.e., ART coverage increasing from 49% to 82% among men and from 69% to 83% among women) and sustained for ten years. We projected the number of TB cases, deaths, and 15 disability-adjusted life years (DALYs) averted relative to standard, clinic-based care. We 16 17 calculated program costs and incremental cost-effectiveness ratios from the provider perspective. **Results:** 18

If community-based ART care could be implemented with similar effectiveness to the DO ART 19 20 trial, increased ART coverage could reduce TB incidence by 27.0% (range 21.3% - 34.1%) and 21 TB mortality by 36.0% (range 26.9% - 43.8%) after ten years. Increasing both ART and TPT uptake through community-based ART with TPT care could reduce TB incidence by 29.7% 22 (range 23.9% - 36.0%) and TB mortality by 36.0% (range 26.9% - 43.8%). Community-based 23 24 ART with TPT care reduced gender disparities in TB mortality rates by reducing TB mortality among men by a projected 39.8% (range 32.2% - 46.3%) and by 30.9% (range 25.3% - 36.5%) 25 26 among women. Over ten years, the mean cost per DALY averted by community-based ART with 27 TPT care was \$846 USD (range \$709 - \$1,012).

28 **Conclusions:**

By substantially increasing coverage of ART and TPT, community-based care for people living

- 30 with HIV could reduce TB incidence and mortality in settings with high burdens of HIV-
- 31 associated TB and reduce TB gender disparities.

32 Introduction

Tuberculosis (TB) is the leading cause of death globally among people living with HIV 33 34 (PLWH) [1]. HIV infection markedly increases the risk of progression to active TB disease [2]. The burden of HIV-associated TB is particularly high in South Africa, where more than 50% of 35 36 people with incident TB in 2021 also had HIV, compared to a global mean of 6.7% [1]. Despite frequent co-occurrence, TB and HIV exhibit different gender disparity patterns in South Africa, 37 where TB prevalence nationally is higher among men compared to higher HIV prevalence 38 among women [3,4]. Multiple factors likely contribute to greater TB burden among men, 39 40 including gender differences in accessing health care, gender-specific contact patterns, and 41 higher prevalence of exposures that increase risk for TB infection and/or progression (e.g., mining, incarceration, use of alcohol, illicit substances, and tobacco) [5–7]. Additionally, gender 42 disparities in HIV outcomes include lower levels of HIV viral suppression among men than 43 44 women living with HIV across nearly all regions globally and in South Africa [8]. The higher 45 detectable viral loads in men contributes in part to higher incidence among women [1].

TB preventive treatment (TPT) when given with antiretroviral therapy (ART), reduces 46 the risk of TB by approximately one third [9–11]. Between 2018 and 2020, over six million 47 PLWH accessed TPT globally, exceeding the target set at the 2018 UN High-Level Meeting on 48 49 Tuberculosis. However, disruptions in care during the COVID-19 pandemic were associated 50 with a 21% decline in the number of people taking TPT between 2019 and 2020 [1]. While global TPT figures are not disaggregated by gender, some studies conducted between 2020 and 51 52 2021 in sub-Saharan Africa found lower rates of TPT initiation and completion among men than 53 among women [12,13], while others did not find differences [14,15].

Differentiated models of care tailor health care delivery to client needs and often extend 54 55 care beyond traditional facility settings and involve an additional cadre of health workers [16]. Differentiated community-based care models have been effective and cost-effective interventions 56 57 for HIV and TB care in sub-Saharan Africa [17], and can improve healthcare by caring for 58 PLWH outside of health facilities. Recently, the Delivery Optimization for Antiretroviral 59 Therapy (DO ART) household-randomized trial of community-based ART initiation and treatment in South Africa and Uganda demonstrated that community-based care increases the 60 61 proportion of PLWH who achieve viral suppression, particularly among men [18]. This 62 overcame a gender disparity in viral suppression that was observed in facility-based care models.

63 At South African DO ART sites, asymptomatic participants in the community-based care group without contraindications to TPT were offered TPT starting one month after ART initiation, 64 65 while the standard clinic group received TPT per routine clinic procedures. TPT uptake was higher among participants who received community-based care than participants who received 66 facility-based care [19]. A recent modelling analysis concluded that community-based HIV 67 treatment was cost-effective in preventing death and disability due to HIV [20]. However, the 68 69 longer-term impact of increased ART and TPT uptake on incident TB and TB deaths were not 70 quantified among trial participants, nor were TB incidence or deaths quantified among 71 community members who were not in the trial.

In this modeling study, we aim to quantify the health impact and cost-effectiveness of extending community-based ART and TPT care to population scale in a TB-HIV high-burden setting of KwaZulu-Natal, South Africa, including analysis of gender disparities in health outcomes. In KwaZulu-Natal, where approximately 70% of people who develop TB also have HIV [21], we hypothesize that reaching the ART and TPT coverage levels achieved in the DO ART trial among all PLWH would substantially reduce TB disease and deaths and reduce gender disparities in TB.

79

80 Methods

81 Study Design and Setting

We developed a dynamic transmission model to simulate TB and HIV outcomes in KwaZulu-82 83 Natal, South Africa. We modeled three care delivery programs, including standard facility-based 84 ART and TPT care (Program 1), community-based ART while assuming the number of 85 individuals initiating TPT occurs at the facility-based care rate (Program 2), and community-86 based ART with TPT care (Program 3). Program 2 was not implemented in DO ART, but is 87 modeled to evaluate the independent effects of ART and TPT. We executed the model over a 10-88 year intervention period to project health and economic outcomes - including TB incidence, TB mortality, disability-adjusted life years (DALYs), and costs – for each care delivery program. 89

90 Dynamic Transmission Model

The dynamic transmission model is stratified by TB stage, HIV stage, TB and HIV treatment status, TB drug resistance status, and gender. We simulate a population of 100,000 persons that

represent the adult population (ages 15-59) of KwaZulu-Natal, South Africa. The population
moves through the compartments at transition rates reflecting TB and HIV infection, disease
progression, treatment and recovery from TB, death, and aging into and out of the system (Fig.
1). The system of ordinary differential equations is described in the appendix, and is solved in R
using the deSolve package in time steps of one month [22]. Model code is available in a public
repository (https://github.com/cgreene3/epi_model_HIV_TB_KZN_SA).

TB transitions





Figure 1. Illustration of TB and HIV dynamic transmission model. Rates of flow between 100 101 each compartment are governed by differential equations, as described in the appendix. Although not visualized here, each TB and HIV compartment is stratified across two TB drug-resistance 102 categories and two genders. The latent TB infection (LTBI) compartment is distinguished by 103 those infected within two years, considered recent, and more than two years, considered remote. 104 The rate of TB preventive treatment (TPT) and antiretroviral therapy (ART) initiations 105 (highlighted in green) are directly impacted by care delivery programs (Table 2). ART coverage 106 107 is used to calculate ART initiation rates so that the proportion of PLWH on ART by gender

108 corresponds to ART coverage assumptions. The active TB compartment is highlighted in red to109 emphasize the compartment capturing incident TB.

The model includes TB compartments for uninfected, latent TB infection (LTBI), active TB disease, and recovered/treated populations, with LTBI divided into recently infected (within two years), and remotely infected (more than two years). Those with recent infections have a higher probability of progression to active TB [23]. The model considers drug-susceptible TB (DS-TB) and multi-drug-resistant TB (MDR-TB) infections. We define MDR-TB as resistant to isoniazid and rifampicin and assume that individuals taking TPT are not protected against acquiring an MDR-TB infection.

The model includes HIV compartments for people living without HIV, PLWH with 117 CD4>200, with CD4≤200, and taking ART (any CD4 count). Annual gender-specific HIV 118 incidence estimates for KwaZulu-Natal, South Africa are incorporated from the Global Burden 119 120 of Disease, Risk Factors, and Injuries Study 2019 (GBD 2019) [24] and the Data-driven Recommendations for Interventions against Viral Infection model [25], as described in the 121 122 appendix. Model parameters that differ by HIV characteristics include the relative transmissibility of TB [26, 27], risk of progression to active TB [28–32], duration of active TB 123 124 [33], and mortality rates [28-32], each of which is calibrated to account for parameter uncertainty (Table 1). PLWH are eligible for TPT regardless of LTBI infection status, reflecting 125 guidance that TPT should not be delayed among PLWH for lack of available LTBI testing [34]. 126 We assume that only people on ART initiate TPT. 127

The population with active TB contributes to the force of infection for new LTBI among 128 129 the susceptible population. The model allows different effective contact rates by gender, which 130 are calibrated, but assumes homogeneous mixing in the population. The simulated population is 131 kept constant at 100,000 by setting the total population entering the model equal to the total population exiting the model (due to aging out or dying). We ran the dynamic transmission 132 133 model from the beginning of 1940 to the end of 2027, with a warmup and calibration period from 1940 through the end of 2017, and the intervention period from the start of 2018 through the end 134 of 2027. We introduced HIV incidence in 1980. 135

We accounted for parameter uncertainty by calibrating 34 parameters using values 25% above and below the mean (Table 1). We used Latin hypercube sampling to generate 100,000 parameter sets for all 34 calibrated parameters [35]. We used each parameter set to execute the

model from 1940-2017. Metrics from the model outputs for each parameter set were evaluated
against 10 calibration target ranges in 2005 and 2017. The calibration target metrics were TB
incidence and TB mortality by HIV status (HIV-positive and HIV-negative) and gender, and
HIV prevalence by gender for adults aged 15-59 in KwaZulu-Natal, South Africa, from GBD
2019 [24]. We accepted parameter sets if all 20 metrics fell within the 95% uncertainty intervals
of the calibration targets, resulting in 859 accepted parameter sets.

Table 1: Dynamic transmission model input parameters. The input parameters used in the

147 calibration with a mean value and range of 25% from the mean.

Parameter description	Value [Range]	Reference (s)
Parameters that Impact F	orce of Infection with TB	
Number of effective contacts per infectious year		[36]
for:		
Males	14 [10.5, 17.5]	
Females	14 [10.5, 17.5]	
Relative transmissibility of TB (per year) for:		[26, 27]
HIV-	1 (reference value)	
HIV+, Not on ART, $CD4 > 200$	0.9 [0.675, 1.125]	
HIV+, Not on ART, CD4 <= 200	0.6 [0.45, 0.75]	
HIV+, On ART	0.9 [0.675, 1.125]	
Fraction of new TB infections that are MDR-TB	0.037 [0.02775, 0.04625]	[37]
Diminished risk of acquiring latent DS-TB		[38]
infection while on TPT for those who are	0.43 [0.3225, 0.5375]	
uninfected		
Increased risk of reinfection after developing active	4 [3, 5]	[39]
ТВ		
Partially protective effect of LTBI against	0.4 [0.3, 0.5]	[18, 26–28]
acquiring a new TB infection		
Parameters that Desc	ribe TB Progression	
Duration of TPT course	6 months (fixed value)	[18]
Duration of LTBI recently infected period	2 years (fixed value)	[23]
Annual rate of progression from:		
Recent LTBI to active TB	0.025 [0.01875, 0.03125]	[43,44]
Remote LTBI to active TB	0.001 [0.00075, 0.00125]	[45,46]
Relative risk of TB progression from LTBI to		[28–32]
active TB:		
HIV-	1 (reference value)	
HIV+, Not on ART, $CD4 > 200$	10 [7.5, 12.5]	
HIV+, Not on ART, CD4 <= 200	17 [12.75, 21.75]	
HIV+, On ART	3 [2.25, 5.25]	

Annual rates of progression among PLWH and on		
ART (IPT efficacy against DS TB)		
LTBI on TPT to active TB	0.0113 [0.0085, 0.0142]	[11]
LTBI after TPT to active TB	0.0113 [0.0085, 0.0142]	[11]
Duration of active TB (if death does not occur) for:		[33]
HIV-	2.0 years [1.5, 2.5]	
HIV+, Not on ART, $CD4 > 200$	1.5 years [1.125, 1.875]	
HIV+, Not on ART, CD4 <= 200	1.5 years [1.125, 1.875]	
HIV+, On ART	1.5 years [1.125, 1.875]	
Rate of TB relapse per year	0.01 [0.0075, 0.0125]	[47]
Parameters that Descr	ribe HIV Progression	
HIV incidence time-varying rates [†] for:		[24]
Males	See appendix	
Females	See appendix	
Duration from HIV acquisition to CD4 <200:		[48]
Males	7.72 years [5.79, 9.65]	
Females	10.25 years [7.6875, 12.8125]	
Parameters that Desc	ribe Mortality Rates	
Baseline mortality time-varying rates ^{\dagger} for:		[24]
Males	See appendix	
Females	See appendix	
Increased risk of mortality for populations:		[30,49–54]
No active TB and HIV-	1 (reference value)	
Active TB, HIV-	15.5 [11.625, 19.375]	
Active TB, HIV+, Not on ART, CD4 > 200	26 [19.5, 32.5]	
Active TB, HIV+, Not on ART, $CD4 \le 200$	50 [37.5, 62.5]	
Active TB, HIV+, On ART	18.5 [13.875, 23.125]	
No active TB, HIV+, Not on ART, CD4 > 200	8 [6, 10]	
No active TB, HIV+, Not on ART, $CD4 \le 200$	26 [19.5, 32.5]	
No active TB, HIV+, On ART	1.35 [1.2, 1.5]	
Parameters that Describe Entries and Exits due t	o Aging	
Proportion of the population that enters each	See appendix	[24]
compartment, time-varying		

[†]Description of time-varying parameter calculations and mean values are in the appendix.

149

150 Care Delivery Programs

151 We executed the model with the 859 accepted calibrated parameter sets for the three care

delivery programs over a 10-year intervention period from the start of 2018 to the end of 2027.

153 The programs differ in their gender-specific ART coverage and TPT initiation rates (Table 2).

154 We assumed that programs took full effect at the start of the intervention period and were

maintained over 10 years. Program 1 and Program 3 reflect the levels of ART coverage and TPT
initiation rates observed in the facility-based care arm and the community-based care arm of the
DO ART trial, respectively. Program 2 reflects the levels of ART coverage observed in Program
3, and assumes that TPT initiation occurs at the facility-based care rate as observed in Program 1.

159 ART coverage estimates are based on the proportion of PLWH who achieve viral suppression under facility-based care (Program 1) and community-based care (Program 3) in the 160 161 DO ART trial [18]. The proportion of PLWH on ART who achieve viral suppression and the proportion of PLWH diagnosed with HIV are based on population-based survey data [4]. The 162 community-based care arm of the DO ART trial includes community-wide HIV testing, so we 163 assume that all PLWH in Program 3 know their status. TPT initiation rates for Program 2 reflect 164 the TPT initiation rates among all PLWH in Program 1, so that the number of individuals 165 initiating TPT in Program 1 and Program 2 are comparable. Details are in the appendix. 166

167

168 Table 2: Facility-based and community-based care programs and parameters over the 169 intervention period.

Program Name		ART Coverage %		TPT initiation %	
				among PLV	VH on ART
		Male	Female	Male	Female
1.	Standard facility-based ART and TPT care	49	69	29	27
2.	Community-based ART care with standard facility-based TPT care	82	83	17	22
3.	Community-based ART with TPT care	82	83	70	75

171

172 Cost Model

The cost model includes costs of TB and HIV-related care from the program perspective (Table 3). Further details of the component costs are in the appendix. The annual outpatient HIV care costs with community ART delivery is estimated at \$310 per person based on a micro-costing study conducted during the DO ART trial under the "efficient at scale" scenario [18] and \$249 per person for facility-based ART delivery. Inpatient and outpatient HIV care costs exclude the cost of care for TB, which is calculated separately [55]. The estimated HIV testing cost is based on the assumption that programs typically test multiple individuals for HIV before finding an

180 eligible person to initiate ART screening. The cost of a six-month course of TPT includes the isoniazid cost [56], clinician time [57], the probability of developing drug-induced liver injury 181 182 from isoniazid [11] and the costs of care for drug-induced liver injury [58]. TB care costs are estimated for standard treatment courses and reflect a higher treatment cost for MDR-TB [59] 183 than for DS-TB [57]. We converted costs from the reported currency to 2018 US dollars using 184 the consumer price index in South Africa and the United States related to the reported currency, 185 186 and the currency conversion from the South African Reserve. We discounted future costs by 3%. We applied HIV- and TB-related costs to the populations in relevant model compartments at 187 each time step and summed the total HIV and TB-related costs for each care program under the 188

- 189 intervention period.
- 190

Table 3: Cost model input parameters. All values are presented as per person costs in 2018
USD and are rounded to the nearest dollar.

Cost category	Value	Reference
Annual outpatient HIV care costs for PLWH who are ^{\pm} :		
Not on ART	135	[60]
On ART under facility-based care (Program 1)	249	[18]
On ART under community-based care (Programs 2 and 3)	310	[18]
Annual inpatient HIV care costs for PLWH who are [±] :		
Not on ART, CD4 >200	62	[55]
Not on ART, CD4 ≤ 200	162	[55]
On ART (regardless of facility or community-based care)	151	[55]
Cost of HIV testing to find one person to initiate ART	24	[18, 55]
Cost of a 6-month course of TPT with isoniazid	20	[11,56–58]
Cost of a course of TB treatment for people with:		
Drug-susceptible TB	259	[57]
Multidrug-resistant TB	1889	[59]

[±]Inpatient and outpatient HIV care costs exclude the cost of care for TB, which is considered
separately.

195

196 Analysis

197 We calculated TB- and HIV- associated DALYs as the sum of years lived with disability (YLD)

and years of life lost (YLL) during the 10-year intervention period using disability weights from

199 GBD 2019 [61]. YLL is based on the gap between the time of death and the end of the

200 intervention period. For example, if an individual died at the start of the eighth year of the

intervention period, the YLL is two years. We discounted costs and DALYs accrued during the
10-year intervention period by 3%. The incremental cost-effectiveness ratios (ICERs) per TB
death, per incident TB case, and per DALY averted are calculated for each care program over the
intervention period. We assessed cost-effectiveness relative to the threshold of \$590 USD per
DALY averted based on the opportunity cost at the margin of the South African program [62,
63], as in Bershteyn, et al. [64]. We conducted one-way sensitivity analyses by varying the cost
parameters in the model using the mean metrics from the 859 accepted parameter sets.

208

209 **Results**

210 Figure 2 illustrates the projected annual TB incidence and mortality rates by gender from 1990 to 2027. In 2017, the year before the start of the intervention, the estimated annual incidence of 211 212 active TB disease was slightly higher for women (1,406 per 100,000; range 1,141 - 1,577) than for men (1,165 per 100,000; range 989 – 1,362). In 2017, nearly 74.7% (1,050 out of 1,406) of 213 214 women with incident TB were also living with HIV, compared to 62.4% (727 out of 1,165) of 215 men with incident TB also living with HIV. However, the estimated TB mortality rate in 2017 was higher for men, with an estimate of 240 (range 174 - 309) per 100,000 men compared with 216 135 (range 103 – 188) per 100,000 women. 217

Over the 10-year intervention period, an estimated 31,009 (range 25,674 – 39,021) PLWH received a course of TPT in Program 3 compared to 17,264 (range 14,156 – 21,255) in Program 1 and 18,221 (range 15,305 – 22,370) in Program 2 (see appendix for details). The estimated number needed to treat with TPT to prevent one case of active TB was 38.

As illustrated in Figure 2, the benefits of community-based care programs (Programs 2 and 3) compared to standard facility-based care (Program 1) are most apparent at the end of the intervention period. TB incidence and mortality rates by gender under each program in the last year of the intervention period are provided in Table 4. Community-based ART with TPT care (Program 3) reduced gender disparities in TB mortality compared to standard facility-based ART and TPT care (Program 1). TB mortality declined by 39.9% (range 32.2% – 46.3%) among men and 30.6% (range 25.3% - 36.5%) among women under Program 3 versus Program 1.

229



Figure 2. Estimated TB incidence and mortality by gender. The mean, maximum, and minimum yearly TB incidence and mortality rates from 1990-2017 over the 859 accepted parameter sets are shown in grey (dots). The mean, maximum, and minimum yearly TB incidence and mortality rates during the intervention period (2018-2027) over the 859 accepted parameter sets are illustrated by care-delivery program. During the intervention period, Program 1 (standard facility-based ART and TPT care) is shown in blue (dots), Program 2 (community-based ART care with standard facility-based TPT care) is shown in green (stars), and Program 3 (community-based ART with TPT care) is shown in red (diamonds).

Table 4: Estimated TB incidence and mortality by care-delivery programs in the last year

of the intervention period. The mean, maximum, and minimum yearly TB incidence and mortality rates are estimated over the 859 accepted parameter sets.

	Program 1	Program 2	Program 3	
	Standard facility-	Community-based	Community-based ART	
	based ART and TPT	ART care with	with TPT care	
	care	standard facility-		
		based TPT care		
	Mean [Min, Max]	Mean [Min, Max]	Mean [Min, Max]	
	TB i	ncidence		
TB incidence rate	1 1/1 [077 1 301]	700 [665, 050]	775 [654, 902]	
per 100,000 males	1,141 [977, 1,301]	799 [005, 950]		
TB incidence rate	1 204 [1 195 1 561]	1 0/6 [883 1 220]	1 004 [949 1 155]	
per 100,000 females	1,394 [1,103, 1,301]	1,040 [883, 1,220]	1,004 [848, 1,155]	
	TB n	nortality		
TB mortality rate	243 [184 200]	1/0 [111 101]	146 [110 194]	
per 100,000 males	245 [164, 500]	149 [111, 191]	140 [110, 164]	
TB mortality rate	124 [102 174]	05 [70 125]	93 [69, 120]	
per 100,000 females	134 [105, 174]	95 [70, 125]		

249

The model projected that community-based care programs also had indirect health benefits for people without HIV through reduced community TB transmission even though ART and TPT were only taken by PLWH. In 2027, TB incidence was 12.9% (range 8.3% – 18.1%) lower among men without HIV and 9.6% (range 4.7% – 15.1%) lower among women without in HIV under Program 3 versus Program 1. Estimated reductions in TB incidence and mortality for people without HIV by gender are detailed in the appendix.

In Figure 3, we illustrate the population-level impact of each program by comparing TB 256 incidence and mortality rates, per 100,000 individuals over the intervention period. We estimated 257 the impact of offering community-based ART (without changing TPT uptake) by comparing 258 outcomes in Program 2 to Program 1. In 2027, Program 2 could reduce the TB incidence rate by 259 27.0% (range 21.3% - 34.1%) and the TB mortality rate by 34.6% (range 24.8% - 42.2%) 260 261 compared to Program 1 (Figure 3). We estimated the impact of offering community-based TPT with ART by comparing outcomes in Program 3 to Program 2. In 2027, Program 3 could reduce 262 TB incidence by an additional 3.6% (range 0.2% - 9.9%) and TB mortality rates by 2.2% (range 263 0.1% - 7.6%) compared to Program 2. 264





Figure 3: Estimated TB incidence and mortality by care-delivery program. The mean, maximum, and minimum yearly TB incidence and mortality rates are estimated over the 859 accepted parameter sets. Program 1 (standard facility-based ART and TPT care) is shown in blue (dots), Program 2 (community-based ART care with standard facility-based TPT care) is shown in green (stars), and Program 3 (community-based ART with TPT care) is shown in red (diamonds).

Health outcomes (DALYs, TB incident cases, TB deaths) and costs are summed over the

273 10-year intervention period for each care program, shown in Table 5. These program health

outcomes and costs are used to calculate incremental health gains, costs, and ICERs for the

outcomes of DALYs, incident TB cases, and TB deaths between facility-based and community-

			1 11				m 11	~
276	based	care	deliverv	programs	as	ın	Table	6.
				0				-

- 277
- 278
- 279 280
- 281
- 282
- 283
- 284 285
- 286
- 287
- 288
- 289 290

291

- 292
- 293
- 294

Table 5: Cumulative health outcomes and costs over the intervention period by program.

Values are the mean, minimum, and maximum values of the 859 accepted parameter sets. Health
 outcomes and costs are summed over the 10-year intervention period for a population of 100,000
 individuals. Discounted values are presented in 2018 values and use an annual discount rate of
 3%.

	Program 1	Program 2	Program 3	
	Standard facility-	Community-based ART	Community-based	
	based ART and TPT	care with standard	ART with TPT care	
	care	facility-based TPT care		
	Mean [Min, Max]	Mean [Min, Max]	Mean [Min, Max]	
Health Outcomes	and Costs (Undiscour	nted)		
DALYs	82 0 [70 5 02 2]	507 [52 4 67 2]	50 5 [52 2 66 0]	
(thousands)	82.0 [70.3, 92.2]	<i>39.1</i> [<i>32.</i> 4, 07.2]	59.5 [52.2, 00.9]	
TB incident cases	127[105 147]	100 [0 1 12 1]	07[91 116]	
(thousands)	12.7 [10.3, 14.7]	10.0 [8.1, 12.1]	9.7 [8.1, 11.6]	
TB deaths	1 9 [1 4 2 2]	12[10 17]	12[10]17]	
(thousands)	1.0 [1.4, 2.3]	1.3 [1.0, 1.7]	1.5 [1.0, 1.7]	
Program costs	00 3 [00 6 11/1]	118 2 [107 / 125 5]	118 / [107 6 125 8]	
(millions in USD)	99.3 [90.0, 114.1]	110.2 [107.4, 155.5]	110.4 [107.0, 155.0]	
Health Outcomes	and Costs (Discounted	<i>d</i>)		
DALYs	72 / [62 1 92 5]	52 8 [47 1 60 5]	53 6 [47 60 2]	
(thousands)	75.4 [05.1, 62.5]	55.6 [47.1, 00.5]	55.0 [47, 00.2]	
TB incident cases	11 2 [0 2 12 0]	88[72 107]	96171 1021	
(thousands)	11.2 [9.2, 12.9]	0.0 [7.2, 10.7]	8.0[/.1, 10.3]	
TB deaths	16[12]2]	1 2 [0 0 1 5]	1.1 [0.9, 1.5]	
(thousands)	1.0 [1.2, 2]	1.2 [0.7, 1.3]		
Program costs	87 1 [79 5 100 1]	102 7 [04 2 119 0]	103.9 [94.4, 119.2]	
(millions in USD)	07.1 [79.3, 100.1]	103.7 [74.3, 110.7]		

315 Table 6: Incremental health gains, costs, and incremental cost-effectiveness ratios (ICERs)

between community-based and facility-based care delivery programs. Health outcomes and

costs are summed over the 10-year intervention period for a population of 100,000 individuals.

Values are the mean, minimum, and maximum values over 859 parameter sets. Discounted

- values are presented in 2018 values and use an annual discount rate of 3%.
- 320

	Program 2 vs.	Program 3 vs.	Program 3 vs.	
	Program 1	Program 1	Program 2	
	Community-based ART	Community-based	Community-based ART	
	with standard facility-	ART with TPT care	with TPT care vs.	
	based TPT care vs.	vs. facility-based	community-based ART	
	facility-based ART and	ART and TPT care	with facility-based TPT	
	TPT care		care	
	Mean [Min, Max]	Mean [Min, Max]	Mean [Min, Max]	
Incremental Healt	h Gains and Costs (Undis	counted)		
DALYs averted	22 2 [10 1 27]	22 5 [19 2 27 2]	0.2 [0.05]	
(thousands)	22.5 [18.1, 27]	22.3 [16.2, 27.5]	0.2 [0, 0.3]	
TB incident cases				
averted	2.7 [2.1, 3.5]	3.0 [2.3, 3.7]	0.3 [0, 0.9]	
(thousands)				
TB deaths averted	0.5 [0.2, 0.7]	0.5 [0.4.07]	0.0.[0.0.0.1]	
(thousands)	0.5 [0.3, 0.7]	0.5 [0.4, 0.7]	0.0 [0.0, 0.1]	
Incremental costs	10.0[10.0.01.5]	10.0[17.0] 21.71	0.2 [0.1.0.2]	
(millions in USD)	18.8 [10.8, 21.5]	19.0 [17.0, 21.7]	0.2 [0.1, 0.3]	
Incremental Healt	h Gains and Costs (Disco	unted)		
DALYs averted	10.7 [15.0.22.9]	10.9 [16.0. 24.0]	0.1.[0.0.0.4]	
(thousands)	19.7 [13.9, 25.8]	19.8 [10.0, 24.0]	0.1 [0.0, 0.4]	
TB incident cases				
averted	2.3 [1.8, 3.0]	2.6 [2.0, 3.2]	0.3 [0.0, 0.8]	
(thousands)				
TB deaths averted	0.4 [0.2, 0.6]	04[02.06]	0.0.[0.0.0.1]	
(thousands)	0.4 [0.3, 0.0]	0.4 [0.3, 0.0]	0.0 [0.0, 0.1]	
Incremental costs	166[149 190]	167[140 101]	0.2 [0.1.0.2]	
(millions in USD)	10.0 [14.0, 10.9]	10.7 [14.9, 19.1]	0.2 [0.1, 0.5]	
Incremental Cost-	effectiveness Ratios (Heal	lth gains and costs are	discounted by 3%)	
Cost per DALY	843	846	1,967	
averted (in USD)	[706, 1,017]	[709, 1,012]	[244, 20,282]	
Cost per incident	7 102	6 / 198	1 109	
TB case averted	[5 161 10 010]	[/ 873 0 30/1	[107 13 012]	
(in USD)			[107, 15,012]	
Cost per TB death	40,692	39,373	19,737	
averted (in USD)	[26,116, 62,157]	[25,606, 57,020]	[1,783, 470,597]	

The community-based ART with TPT care program (Program 3) did not meet the cost-321 effectiveness threshold of \$590 USD per DALY averted with the input parameter costs given in 322 Table 3. Figure 4 shows the impact of varying costs on the discounted incremental cost per 323 DALY averted under Program 3 versus Program 1. The discounted incremental cost per DALY 324 was most sensitive to the cost of outpatient HIV care. If the cost of annual outpatient care for 325 PLWH on ART under community-based ART programs (Programs 2 and 3) were to decrease 326 from \$310 to \$283, or if the cost of annual outpatient care for PLWH on ART under standard 327 facility-based ART and TPT care (Program 1) were to increase from \$249 to \$260, then the 328 discounted incremental cost per DALY would achieve the cost-effectiveness threshold. 329



Figure 4: Sensitivity analysis of the discounted incremental cost per DALY averted by 330 community-based ART with TPT care (Program 3) versus standard facility-based ART 331 and TPT care (Program 1) over the intervention period. The solid line represents the mean 332 discounted incremental cost per DALY averted over the 859 accepted parameter sets of \$846 333 USD per DALY averted. The dashed vertical line represents the cost-effectiveness threshold of 334 335 \$590 USD per DALY averted. The horizontal bars represent the discounted incremental cost per DALY averted at bounds of 25% above of the modeled cost parameter (high) and 25% below the 336 modeled cost parameter (low). All costs are in 2018 USD. 337

338 **Discussion**

Scaling up community-based ART with TPT care to the population level in a high HIV-TB 339 burden setting such as KwaZulu-Natal, South Africa, could avert substantial HIV and TB 340 341 morbidity and mortality, if equivalent effectiveness is maintained as demonstrated in the DO 342 ART trial. The increase in ART coverage achieved through community-based care reduced 343 cumulative TB disease by 21% over ten years, and community-based TPT care reduced it further by 3%. Additionally, though the interventions were only directly delivered to PLWH, the model 344 345 captured indirect benefits of reduced TB incidence disease and mortality among people without 346 HIV under the community ART and TPT scenarios. Prior modeling analyses in South Africa have also found that ART and TPT scale-up would be projected to reduce TB incidence among 347 348 people living with and without HIV [65].

349 Gender disparities in HIV and TB outcomes in this setting are complex and are reflected in the model results. Specifically, the higher HIV prevalence among women (39%) compared to 350 351 men (20%) in our model resulted in higher incidence and mortality of HIV-associated TB among 352 women than among men, while HIV-negative women had lower TB incidence, prevalence, and mortality than HIV-negative men. The larger increase in ART coverage under the community-353 354 based care programs among men resulted in larger percent reductions in 10-year TB-associated 355 mortality among men than among women compared to standard clinic-based care. Gender-356 specific model parameters included effective contact rates, HIV prevalence, HIV disease 357 progression, ART coverage, and baseline (non-HIV and non-TB associated) mortality, though 358 other features of TB epidemiology may also differ by gender, including care seeking behavior 359 that may impact active TB duration and case fatality ratios. A recent gender-specific TB model 360 in a setting with a low HIV prevalence found that interventions targeted to risk factors with a 361 higher prevalence among men (e.g. tobacco smoking and harmful alcohol use) achieved the 362 greatest projected TB incidence reductions among men, but also substantially reduced TB 363 incidence among women and children [66].

Our cost analysis found that community-based ART with TPT care was cost ineffective relative to the cost-effectiveness threshold based on the opportunity cost at the margin of the South African programme [64]. The sensitivity analysis of cost parameters indicated that variation in the costs of outpatient HIV care for PLWH on ART substantially affected the ICER.

368 If the annual per person costs of outpatient HIV care for PLWH on ART under community-based 369 care were to decrease from \$310 to \$283 or the annual per person costs of outpatient HIV care 370 for PLWH on ART under facility-based care were to increase to from \$249 to \$260, then community-based ART with TPT (Program 3) could be cost effective. Other community-based 371 372 interventions, including interval TB/HIV screening and linkage to care, were found to be costeffective in a modeling analysis set in South Africa, though these did not include community-373 374 based HIV treatment and were evaluated against a higher GDP-based cost-effectiveness threshold [68]. 375

376 Strengths of this analysis include that it is based in findings from the recent DO ART randomized controlled trial conducted in this setting. Additionally, the model is calibrated to 377 gender- and province-specific estimates of TB and TB-HIV incidence and mortality at two time 378 points that capture the declines in HIV-associated TB incidence and mortality in the setting of 379 increased ART coverage [5]. To reflect these dynamics, we included time varying parameters for 380 HIV incidence, prevalence, and ART coverage that incorporate historical changes in ART 381 availability. Additionally, the model incorporates uncertainty in model parameters. Uncertainty 382 383 remains in key aspects of TB epidemiology, including the rate of progression from latent to active TB, which is represented differently across models [69]. Finally, by using a model that 384 differentiates compartments by gender, we were able to stratify outcomes by gender, which is 385 386 important for evaluating health program impacts on gender equity in health outcomes.

387 This analysis also has limitations. First, we assumed that the modeled care programs could take effect immediately and be sustained over ten years, which may not be feasible for 388 already-strained health care workforce and budgets. However, dramatic increases in TPT 389 initiation and completion have been observed in some HIV high-incidence settings through 390 391 focused outreach campaigns [70]. Second, the model does not differentiate groups by age despite differences in HIV and TB incidence, prevalence, and mortality by age group due to the 392 393 complexity of calibration across this additional dimension. Third, for simplicity, we assumed that 394 people taking TPT would not be protected from infection with an MDR-TB strain, though some 395 evidence suggests that they may have partial protection from a resistant strain [71]. Finally, the economic analysis is from a health system perspective that does not include patient costs, despite 396 397 numerous studies documenting patient costs and avoiding catastrophic costs as a key focus of TB 398 goals [72].

399

400

401 **Conclusions**

If community-based ART with TPT care was scaled up to achieve similar levels of ART and TPT coverage as in the DO ART trial, the TB and HIV dynamic transmission model predicts that TB disease would be reduced by 24% and deaths reduced by 28% over ten years in KwaZulu-Natal, South Africa. Differentiated models of HIV care can substantially reduce TB morbidity and mortality and reduce gender disparities in TB.

407

408 Competing interests

409 The authors declare no competing interests.

410

411 Authors' contributions

JMR and RVB conceptualized the study. CG formulated and programmed the model, with guidance from ZBZ and parameterization from JMR, CG, CJB, DWR, AES, and DWD. AvH, DAR, AES, and RVB provided critical interpretation of the DO ART trial data. All authors contributed to scenario definition and analysis planning. JMR wrote the first draft of the manuscript. CG wrote the first draft of the appendix. All authors contributed to the interpretation of the findings, provided critical review and revisions, and approved the final version.

418

419 Acknowledgements

- Funding: This work was supported by funding from the Firland Foundation. JMR is supported bythe National Institute of Allergy and Infectious Diseases (K01 AI138620).
- This work was facilitated through the use of advanced computational, storage, and networking infrastructure provided by the Hyak supercomputer system and funded by the STF at the
- 424 University of Washington.

425 Additional files

- 426 Additional file 1: Appendix
- 427 The appendix file contains additional details about the study methods and additional results.
- 428
- 429
- 430

431 **References**

432	1.	World Health Organization. Global Tuberculosis Report. 2022.
433	2.	Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The
434		growing burden of tuberculosis: global trends and interactions with the HIV epidemic.
435		Arch Intern Med [Internet]. 2003 May 12;163(9):1009–21. Available from:
436		http://www.ncbi.nlm.nih.gov/pubmed/12742798
437	3.	Moyo S, Ismail F, Van der Walt M, Ismail N, Mkhondo N, Dlamini S, et al. Prevalence of
438		bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a
439		multistage, cluster-based, cross-sectional survey. Lancet Infect Dis [Internet]. 2022 May
440		17; Available from: http://www.ncbi.nlm.nih.gov/pubmed/35594897
441	4.	Human Sciences Research Council. South African National HIV Prevalence, Incidence,
442		Behaviour and Communication survey, 2017. Towards achieving the UNAIDS 90-90-90
443		targets. 2019 Oct.
444	5.	Ledesma JR, Ma J, Vongpradith A, Maddison ER, Novotney A, Biehl MH, et al. Global,
445		regional, and national sex differences in the global burden of tuberculosis by HIV status,
446		1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis
447		[Internet]. 2021 Sep; Available from:
448		https://linkinghub.elsevier.com/retrieve/pii/S1473309921004497
449	6.	Horton KC, Sumner T, Houben RMGJ, Corbett EL, White RG. A Bayesian Approach to
450		Understanding Sex Differences in Tuberculosis Disease Burden. Am J Epidemiol
451		[Internet]. 2018 Nov 1;187(11):2431–8. Available from:
452		https://doi.org/10.1093/aje/kwy131
453	7.	Horton KC, Hoey AL, Béraud G, Corbett EL, White RG. Systematic Review and Meta-
454		Analysis of Sex Differences in Social Contact Patterns and Implications for Tuberculosis
455		Transmission and Control. Emerg Infect Dis. 2020 May; 26(5):910–9.
456	8.	The Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2021.
457		2021.

458 459	9.	Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al.
460		placebo-controlled trial. Lancet. 2014 Aug;384(9944):682–90.
461	10.	Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early
462		antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9).
463	11.	Ross J, Badje A, Rangaka M, Walker A, Shapiro A, Thomas K, et al. Isoniazid preventive
464		therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review
465		and meta-analysis of individual participant data. The Lancet HIV. 2022 Jan; 8(1): e8-e15.
466	12.	Maokola W, Ngowi B, Lawson L, Robert M, Mahande M, Todd J, et al. Coverage of
467		isoniazid preventive therapy among people living with HIV; A retrospective cohort study
468		in Tanzania (2012-2016). Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021
469		Feb;103:562–7.
470	13.	Sensalire S, Karungi Karamagi Nkolo E, Nabwire J, Lawino A, Kiragga D, Muhire M, et
471		al. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested
472		study from a national QI collaborative in Uganda. AIDS Res Ther. 2020 May;17(1):28.
473	14.	Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, et al.
474		Predictors of isoniazid preventive therapy completion among HIV-infected patients
475		receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care.
476		2020 Jan;32(1):119–27.
477	15.	Takamiya M, Takarinda K, Balachandra S, Godfrey M, Radin E, Hakim A, et al. Isoniazid
478		preventive therapy use among adult people living with HIV in Zimbabwe. Int J STD
479		AIDS [Internet]. 2021;32(11):1020–7. Available from:
480		http://www.ncbi.nlm.nih.gov/pubmed/33978529
481	16.	Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, et al.
482		Reimagining HIV service delivery: the role of differentiated care from prevention to
483		suppression. J Int AIDS Soc [Internet]. 2016;19(1):21484. Available from:
484		http://www.ncbi.nlm.nih.gov/pubmed/27914186

485 486 487 488	17.	Loveday M, Wallengren K, Reddy T, Besada D, Brust JCM, Voce A, et al. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care. PLoS One [Internet]. 2018 Apr 18;13(4):e0196003. Available from: https://doi.org/10.1371/journal.pone.0196003
489 490 491 492	18.	Barnabas RV, Szpiro AA, van Rooyen H, Asiimwe S, Pillay D, Ware NC, et al. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Heal. 2020 Oct;8(10):e1305–15.
493 494 495 496	19.	Shapiro AE, Szpiro AA, Sausi K, Sithole N, Koole O, Krows M, Schaafsma T, Shahmanesh M, van Rooyen H, Celum C, van Heerden A, Barnabas RV. Increased TB preventive therapy coverage with integrated community-based IPT and ART. OA-111. CROI, Feb 2023.
497 498 499 500	20.	Sahu M, Bayer CJ, Roberts DA, van Rooyen H, van Heerden A, Shahmanesh M, et al. Population health impact, cost-effectiveness, and affordability of community-based HIV treatment and monitoring in South Africa: a health economics modelling study. medRxiv. May 2022.
501 502 503	21.	KwaZulu-Natal Health Department. KwaZulu-Natal Department of Health Strategic Plan 2015-2019 [Internet]. 2015. Available from: http://www.kznhealth.gov.za/Strategic-Plan-2015-2019.pdf
504 505	22.	Team RC. R: a language and environment for statistical computing. Vienna, Austria; 2019.
506 507 508	23.	Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age- dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997 Oct;119(2):183–201.
509 510 511 512	24.	Achoki T, Sartorius B, Watkins D, Glenn SD, Kengne AP, Oni T, et al. Health trends, inequalities and opportunities in South Africa's provinces, 1990–2019: findings from the Global Burden of Disease 2019 Study. J Epidemiol Community Health [Internet]. 2022 May;76(5):471–81. Available from: https://jech.bmj.com/lookup/doi/10.1136/jech-2021-

513 217480

514	25.	Rao DW, Bayer CJ, Liu G, Chikandiwa A, Sharma M, Hathaway CL, et al. Modelling
515		cervical cancer elimination using single-visit screening and treatment strategies in the
516		context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa. J Int AIDS
517		Soc [Internet]. 2022 Oct;25(10):e26021. Available from:
518		http://www.ncbi.nlm.nih.gov/pubmed/36225139
519	26.	Martinez L, Woldu H, Chen C, Hallowell BD, Castellanos ME, Lu P, et al. Transmission
520		Dynamics in Tuberculosis Patients with Human Immunodeficiency Virus: A Systematic
521		Review and Meta-Analysis of 32 Observational Studies. Clin Infect Dis. 2020 Aug.
522	27.	Huang C-C, Tchetgen ET, Becerra MC, Cohen T, Hughes KC, Zhang Z, et al. The effect
523		of HIV-related immunosuppression on the risk of tuberculosis transmission to household
524		contacts. Clin Infect Dis. 2014 Mar;58(6):765–74.
525	28.	Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral
526		therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A. 2010
527		Nov;107(45):19485–9.
528	29.	Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated
529		populations with a positive tuberculin skin test or interferon-gamma release assay result:
530		systematic review and meta-analysis. BMJ. 2020 Mar;368:m549.
531	30.	Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-
532		AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected
533		adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis. 2012
534		Mar;54(5):714–23.
535	31.	Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control.
536		Semin Respir Crit Care Med. 2008 Oct;29(5):481–91.
537	32.	Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral
538		therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-
539		analysis. PLoS Med. 2012;9(7):e1001270.

540	33.	Ku C-C. MacPherson P.	Khundi M.	Nzawa Soko RH.	Feasev HRA	. Nliwasa M. et al.
						,

541 Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease

- 542 with a Bayesian analysis of prevalence survey and notification data. BMC Med [Internet].
- 2021;19(1):298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34753468 543
- 544 34. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland; 2018. 545
- Stein M. Large Sample Properties of Simulations Using Latin Hypercube Sampling. 546 35.
- 547 Technometrics [Internet]. 1987 May;29(2):143. Available from:
- https://www.jstor.org/stable/1269769?origin=crossref 548
- van Leth F, van der Werf MJ, Borgdorff MW. Prevalence of tuberculous infection and 549 36.
- incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ 550
- 551 [Internet]. 2008 Jan;86(1):20–6. Available from:
- http://www.ncbi.nlm.nih.gov/pubmed/18235886 552
- World Health Organization. Global Tuberculosis Report. Geneva, Switzerland; 2020. 553 37.
- 554 38. Egsmose T, Ang'awa JO, Poti SJ. The use of isoniazid among household contacts of open 555 cases of pulmonary tuberculosis. Bull World Health Organ [Internet]. 1965;33(3):419–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5321762 556
- 557 Verver S, Warren RM, Bevers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. 39.
- Rate of reinfection tuberculosis after successful treatment is higher than rate of new 558
- 559 tuberculosis. Am J Respir Crit Care Med [Internet]. 2005 Jun 15;171(12):1430–5.
- Available from: http://www.ncbi.nlm.nih.gov/pubmed/15831840 560
- 561 40. Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, et al. Impact of 562 isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an
- epidemiological model. J Acquir Immune Defic Syndr [Internet]. 2014 Aug 15;66(5):552-
- 563
- 8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24853308 564
- Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of 565 41. 566 isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis

567		coinfected populations. Proc Natl Acad Sci U S A [Internet]. 2006 May 2;103(18):7042-
568		7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16632605
569	42.	Sutherland I, Svandová E, Radhakrishna S. The development of clinical tuberculosis
570		following infection with tubercle bacilli. 1. A theoretical model for the development of
571		clinical tuberculosis following infection, linking from data on the risk of tuberculous
572		infection and the incidence of clinic. Tubercle [Internet]. 1982 Dec;63(4):255-68.
573		Available from: http://www.ncbi.nlm.nih.gov/pubmed/6763793
574	43.	Ferebee SH, Mount FW. Tuberculosis Morbidity in a Controlled Trial of the Prophylactic
575		Use of Isoniazid among Household Contacts. Am Rev Respir Dis [Internet]. 1962 Apr
576		1;85(4):490–510. Available from:
577		https://www.atsjournals.org/doi/abs/10.1164/arrd.1962.85.4.490
578	44.	Martinez L, Sekandi JN, Castellanos ME, Zalwango S, Whalen CC. Infectiousness of
579		HIV-Seropositive Patients with Tuberculosis in a High-Burden African Setting. Am J
580		Respir Crit Care Med [Internet]. 2016;194(9):1152-63. Available from:
581		http://www.ncbi.nlm.nih.gov/pubmed/27181053
582	45.	Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the
583		rates of late reactivation tuberculosis: a systematic review. Lancet Infect Dis [Internet].
584		2021; Available from:
585		https://www.sciencedirect.com/science/article/pii/S1473309920307283
586	46.	Glynn JR, Khan P, Mzembe T, Sichali L, Fine PEM, Crampin AC, et al. Contribution of
587		remote M.tuberculosis infection to tuberculosis disease: A 30-year population study. PLoS
588		One [Internet]. 2023;18(1):e0278136. Available from:
589		http://www.ncbi.nlm.nih.gov/pubmed/36706117
590	47.	Connolly C, Reid A, Davies G, Sturm W, McAdam KPWJ, Wilkinson D. Relapse and
591		mortality among HIV-infected and uninfected patients with tuberculosis successfully
592		treated with twice weekly directly observed therapy in rural South Africa. AIDS
593		[Internet]. 1999;13(12). Available from:
594		$https://journals.lww.com/aidsonline/Fulltext/1999/08200/Relapse_and_mortality_among_nd_mortality_among_nd_mortality_among_nd_mortality_among_nd_mortality_among_nd_mortality_among_nd_mortality_among_nd_mortality_$

595 HIV_infected_and.15.aspx

596 597 598 599	48.	Ross JM, Ying R, Celum CL, Baeten JM, Thomas KK, Murnane PM, et al. Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics [Internet]. 2018;23:34–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29223580
600 601 602	49.	Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb;362(8):697–706.
603 604 605	50.	Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet. 1995 Mar;345(8950):607–10.
606 607 608	51.	Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. The Lancet. 2006 Oct;368(9543):1254–9.
609 610 611 612	52.	Nglazi MD, Bekker L-G, Wood R, Kaplan R. The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: a retrospective cohort study. BMC Infect Dis. 2015 Nov;15:536.
613 614 615 616	53.	Osman M, Seddon JA, Dunbar R, Draper HR, Lombard C, Beyers N. The complex relationship between human immunodeficiency virus infection and death in adults being treated for tuberculosis in Cape Town, South Africa. BMC Public Health. 2015 Jun;15:556.
617 618 619	54.	Pepper DJ, Schomaker M, Wilkinson RJ, de Azevedo V, Maartens G. Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. AIDS Res Ther. 2015;12:35.
620 621	55.	Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient costs of HIV services in South Africa: Systematic review and application in the South

622		African HIV Investment Case. PLoS One. 2019;14(2):e0210497.
623	56.	South Africa Master Health Product List [Internet]. 2021. Available from:
624		http://www.health.gov.za/tenders/
625	57.	Bozzani FM, Mudzengi D, Sumner T, Gomez GB, Hippner P, Cardenas V, et al.
626		Empirical estimation of resource constraints for use in model-based economic evaluation:
627		an example of TB services in South Africa. Cost Eff Resour Alloc [Internet]. 2018;16:27.
628		Available from: http://www.ncbi.nlm.nih.gov/pubmed/30069166
629	58.	Kim H-Y, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of
630		universal isoniazid preventive therapy among HIV-infected pregnant women in South
631		Africa. Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis. 2018
632		Dec;22(12):1435–42.
633	59.	Masuku SD, Berhanu R, Van Rensburg C, Ndjeka N, Rosen S, Long L, et al. Managing
634		multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc
635		Lung Dis [Internet]. 2020 Apr 1;24(4):376–82. Available from:
636		https://www.ingentaconnect.com/content/10.5588/ijtld.19.0409
637	60.	Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART
638		for treatment and prevention of HIV in South Africa: estimated cost and cost-
639		effectiveness 2011-2050. PLoS One. 2012;7(2):e30216.
640	61.	Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019
641		(GBD2019). Disability Weights. 2020.
642	62.	Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-
643		pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV
644		Investment Case. PLoS One [Internet]. 2017;12(10):e0186496. Available from:
645		http://www.ncbi.nlm.nih.gov/pubmed/29073167
646	63.	Phillips AN, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, et al.
647		Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in
648		KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis [Internet]. 2021 Apr

649		23;223(8):1345–55. Available from:
650		https://academic.oup.com/jid/article/223/8/1345/5680588
651 652 653 654 655	64.	Bershteyn A, Jamieson L, Kim HY, Platais I, Milali MP, Mudimu E, et al. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. The Lancet Global Health, Volume 10, Issue 9, 2022 Sept; Pages e1298-e1306. Available from: https://doi.org/10.1016/S2214-109X(22)00310-2.
656 657 658	65.	Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, et al. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS. 2019 Mar;33(3):525–36.
659 660 661 662 663	66.	Horton KC, White RG, Hoa NB, Nguyen HV, Bakker R, Sumner T, et al. Population benefits of addressing programmatic and social determinants of gender disparities in tuberculosis in Viet Nam: A modelling study. Gianella Malca C, editor. PLOS Glob Public Heal [Internet]. 2022 Jul 14;2(7):e0000784. Available from: https://dx.plos.org/10.1371/journal.pgph.0000784
664 665 666 667 668	67.	Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, et al. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. Lancet Glob Heal [Internet]. 2022 Nov;10(11):e1646–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36240830
669 670 671	68.	Gilbert JA, Shenoi S V, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost- Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One. 2016;11(12):e0165614.
672 673 674 675 676	69.	Menzies NA, Wolf E, Connors D, Bellerose M, Sbarra AN, Cohen T, et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect Dis [Internet]. 2018 Aug;18(8):e228–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29653698

677	70.	Musaazi J, Sekaggya-Wiltshire C, Okoboi S, Zawedde-Muyanja S, Senkoro M, Kalema
678		N, et al. Increased uptake of tuberculosis preventive therapy (TPT) among people living
679		with HIV following the 100-days accelerated campaign: A retrospective review of
680		routinely collected data at six urban public health facilities in Uganda. medrxiv. 2022;
681	71.	Huang C-C, Becerra MC, Calderon R, Contreras C, Galea J, Grandjean L, et al. Isoniazid
682		Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis. Am J Respir Crit
683		Care Med. 2020 Jun.
684	72.	Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic
685		burden of TB diagnosis and treatment in South Africa. Soc Sci Med [Internet]. 2015
686		Apr;130:42–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25681713
687		